A Phase 2 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Active comparator in Venous Thrombosis, sponsored by Bayer. Completed at 59 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-09-21.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing rivaroxaban in Venous Thrombosis — 5 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Venous Thrombosis.
Among the 36 studies testing rivaroxaban in Venous Thrombosis, this one is the 27th largest by enrollment, is one of 3 that started in 2013, is one of 4 in phase 2, and was the 8th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →5 of the 36 studies testing rivaroxaban in Venous Thrombosis are open now, in 6 countries. Recruiting first, the newest first:
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Prof. Stavros Konstantinides, MD · Sites in Austria, Germany
Ages 18–85
University Hospital, Angers · Sites in France
Ages 18+
Science Valley Research Institute · Sites in Brazil
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 10
First in 2004; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 120 across the 36 interventional studies. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 36 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
23 studies in Venous Thrombosis by Bayer: none open now, none under way, none of them phase 3. Of 23 finished, 6 (26%) have results posted.
Among the 23 studies in Venous Thrombosis by Bayer, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2013, is one of 5 in phase 2, and was the 9th registered.
Bayer’s Venous Thrombosis studies by the year they started, since 2004.
3 of the studies testing rivaroxaban in Venous Thrombosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06611319Phase 3Prof. Stavros Konstantinides, MDENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty | 2027-03 |
| NCT04694248First Affiliated Hospital of Zhejiang UniversityAnticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting | 2026-12-31 |
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing rivaroxaban in Venous Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 23 in Venous Thrombosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. There will also be a check for bleeding and worsening of blood clots.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects aged from 12 - \<18 years were administered with age and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR (immediate-release) tablet once daily (OD) under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kilogram (kg) received a dose (equivalent to 20 milligram \[mg\] in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Subjects aged from 12 - \<18 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
Drug: Active comparator
Subjects aged from 6 - \<12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kg received a dose (equivalent to 20 mg in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Subjects aged from 6 - \<12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily (BID). Subjects with a body weight of 9 to less than 50 kg received a total daily dose (equivalent to 20 mg in adults) ranging from 6.4 to 15 mg and subjects with a body weight of greater than or equal to 50 kg received a total daily dose of 20 mg.
Drug: Rivaroxaban (BAY59-7939) suspension
Subjects aged from 6 - \<12 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or INR-adjusted (vitamin K antagonist).
Drug: Active comparator
Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
Number of Subjects With Major and Clinically Relevant Non-Major Bleeding Events
Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and: * associated with a fall in hemoglobin of 2 gram/decilitre (g/dL) or more, or * leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or * occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or * contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: * medical intervention, or * unscheduled contact (visit or telephone call) with a physician, or * cessation (temporary) of study treatment, or * discomfort for the child such as pain or * impairment of activities of daily life (such as loss of school days or hospitalization).
Time frame: From start of study drug administration until end of the 30-day treatment period
Number of Subjects With Symptomatic Recurrent Venous Thromboembolism
The occurrence of recurrent venous thromboembolism was summarized by age group. Symptomatic recurrence of venous thrombosis was documented by the appropriate imaging test.
Time frame: From start of study drug administration until end of the 30-day treatment period
Number of Subjects With Asymptomatic Deterioration in Thrombotic Burden
The occurrence of asymptomatic deterioration in thrombotic burden was summarized by age group. Asymptomatic deterioration in thrombotic burden was documented by the appropriate imaging test and the results were classified as normalized, improved, no relevant change, deteriorated, not evaluable or not available.
Time frame: Repeat imaging at the end of the 30 day treatment period
Change From Baseline in Prothrombin Time at Specified Time Points
Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.
Time frame: 0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
Change From Baseline in Activated Partial Thromboplastin Time at Specified Time Points
The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway.
Time frame: 0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
Anti-factor Xa Values at Specified Time Points
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
Time frame: 0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points
Geometric and percentage geometric coefficient of variation (%CV) were reported.
Time frame: 0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
The study was conducted at multiple centers in 10 countries worldwide between 19 February 2013 (first subject first visit) and 01 September 2016 (last subject last visit).
| Milestone | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Comparator, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years | Comparator, Age: 6 - < 12 Years |
|---|---|---|---|---|---|
| Started | 11 | 13 | 13 | 19 | 7 |
| Completed | 11 | 13 | 12 | 19 | 7 |
| Not completed | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and: * associated with a fall in hemoglobin of 2 gram/decilitre (g/dL) or more, or * leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or * occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or * contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: * medical intervention, or * unscheduled contact (visit or telephone call) with a physician, or * cessation (temporary) of study treatment, or * discomfort for the child such as pain or * impairment of activities of daily life (such as loss of school days or hospitalization).
| Participants | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Comparator, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years | Comparator, Age: 6 - < 12 Years |
|---|---|---|---|---|---|
| Major bleeding events | 0 | 0 | 0 | 0 | 0 |
| Clinically relevant non-major bleeding events | 3 | 0 | 0 | 1 | 0 |
The occurrence of recurrent venous thromboembolism was summarized by age group. Symptomatic recurrence of venous thrombosis was documented by the appropriate imaging test.
| Participants | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Comparator, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years | Comparator, Age: 6 - < 12 Years |
|---|---|---|---|---|---|
| Number of Subjects With Symptomatic Recurrent Venous Thromboembolism | 0 | 0 | 0 | 0 | 0 |
The occurrence of asymptomatic deterioration in thrombotic burden was summarized by age group. Asymptomatic deterioration in thrombotic burden was documented by the appropriate imaging test and the results were classified as normalized, improved, no relevant change, deteriorated, not evaluable or not available.
| Participants | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Comparator, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years | Comparator, Age: 6 - < 12 Years |
|---|---|---|---|---|---|
| Normalized | 3 | 2 | 2 | 4 | 1 |
| Improved | 4 | 0 | 8 | 9 | 4 |
| No relevant change | 0 | 0 | 1 | 2 | 0 |
| Deteriorated | 0 | 0 | 0 | 0 | 0 |
| Not evaluable | 0 | 2 | 0 | 0 | 1 |
| Not available | 4 | 9 | 2 | 4 | 1 |
Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.
| seconds | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years |
|---|---|---|---|
| Day 15: 2 to 4 hours post-dose | 8.964 ± 3.822 | 9.083 ± 2.513 | 3.147 ± 2.099 |
| Day 15: 6 to 8 hours post-dose | 4.218 ± 2.977 | 2.817 ± 1.628 | 1.984 ± 1.341 |
| Day 31: 10 to 16 hours post-dose | NA ± NA | NA ± NA | 0.156 ± 1.155 |
| Day 31: 20 to 24 hours post-dose | -0.082 ± 1.020 | -0.327 ± 1.332 | NA ± NA |
The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway.
| seconds | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years |
|---|---|---|---|
| Day 15: 2 to 4 hours post-dose | 10.982 ± 4.470 | 12.818 ± 5.210 | 2.995 ± 5.616 |
| Day 15: 6 to 8 hours post-dose | 6.136 ± 2.641 | 5.900 ± 4.942 | 1.858 ± 4.774 |
| Day 31: 10 to 16 hours post-dose | NA ± NA | NA ± NA | -0.483 ± 6.488 |
| Day 31: 20 to 24 hours post-dose | 1.345 ± 3.190 | 1.240 ± 4.992 | NA ± NA |
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
| microgram per liter (mcg/L) | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years |
|---|---|---|---|
| Day 15: pre-dose | 16.081 ± 6.136 | 8.136 ± 3.069 | 31.553 ± 25.416 |
| Day 15: 2 to 4 hours post-dose | 185.481 ± 53.326 | 252.853 ± 71.072 | 99.415 ± 54.415 |
| Day 15: 6 to 8 hours post-dose | 105.223 ± 54.339 | 68.670 ± 32.845 | 77.929 ± 50.074 |
| Day 31: 10 to 16 hours post-dose | NA ± NA | NA ± NA | 30.927 ± 18.037 |
| Day 31: 20 to 24 hours post-dose | 16.038 ± 7.653 | 8.409 ± 3.664 | NA ± NA |
Geometric and percentage geometric coefficient of variation (%CV) were reported.
| microgram per liter (mcg/L) | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years |
|---|---|---|---|
| Day 15: pre-dose | 20.4822 ± 40.6726 | 7.4367 ± 152.9768 | 41.6025 ± 183.6873 |
| Day 15: 2 to 4 hours post-dose | 219.6933 ± 35.7518 | 240.6319 ± 18.3387 | 119.2201 ± 52.9889 |
| Day 15: 6 to 8 hours post-dose | 124.6723 ± 49.1882 | 96.8051 ± 41.8155 | 100.5992 ± 52.6497 |
| Day 31: 10 to 16 hours post-dose | NA ± NA | NA ± NA | 43.5223 ± 81.7283 |
| Day 31: 20 to 24 hours post-dose | 21.3252 ± 43.1274 | 9.4654 ± 167.7545 | NA ± NA |
Collected over From start of study drug administration until 30 day post study treatment. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | — | 0/11 (0%) | 9/11 (81.8%) |
| Comparator, Age: 12 - <18 Years | — | 1/13 (7.7%) | 8/13 (61.5%) |
| Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | — | 0/13 (0%) | 6/13 (46.2%) |
| Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years | — | 2/19 (10.5%) | 12/19 (63.2%) |
| Comparator, Age: 6 - < 12 Years | — | 0/7 (0%) | 2/7 (28.6%) |
| Event | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Comparator, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years | Comparator, Age: 6 - < 12 Years |
|---|---|---|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 0/11 | 1/13 | 0/13 | 0/19 | 0/7 |
| Hypothalamo-pituitary disorderEndocrine disorders | 0/11 | 0/13 | 0/13 | 1/19 | 0/7 |
| Influenza B virus test positiveInvestigations | 0/11 | 0/13 | 0/13 | 1/19 | 0/7 |
| Event | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Comparator, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years | Comparator, Age: 6 - < 12 Years |
|---|---|---|---|---|---|
| MenorrhagiaReproductive system and breast disorders | 4/11 | 0/13 | 0/13 | 0/19 | 0/7 |
| HeadacheNervous system disorders | 2/11 | 0/13 | 2/13 | 3/19 | 0/7 |
| Abdominal painGastrointestinal disorders | 0/11 | 0/13 | 2/13 | 1/19 | 0/7 |
| Abdominal pain upperGastrointestinal disorders | 0/11 | 0/13 | 0/13 | 1/19 | 1/7 |
| DiarrhoeaGastrointestinal disorders | 1/11 | 1/13 | 1/13 | 0/19 | 1/7 |
| VomitingGastrointestinal disorders | 1/11 | 1/13 | 0/13 | 2/19 | 1/7 |
| Chest painGeneral disorders | 1/11 | 0/13 | 0/13 | 0/19 | 1/7 |
| FallInjury, poisoning and procedural complications | 0/11 | 0/13 | 0/13 | 0/19 | 1/7 |
| Vocal cord paralysisNervous system disorders | 0/11 | 0/13 | 0/13 | 0/19 | 1/7 |
| Post thrombotic syndromeVascular disorders | 0/11 | 0/13 | 0/13 | 0/19 | 1/7 |
| Age, Continuous(Years) | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Comparator, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years | Comparator, Age: 6 - < 12 Years | Total |
|---|---|---|---|---|---|---|
| Mean | 15.5 ± 1.2 | 14.8 ± 1.0 | 8.5 ± 2.1 | 8.3 ± 1.9 | 9.0 ± 2.0 | 11.0 ± 3.7 |
| Sex: Female, Male(Participants) | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 12 - <18 Years | Comparator, Age: 12 - <18 Years | Rivaroxaban (BAY59-7939) Tablet, OD, Age: 6 - <12 Years | Rivaroxaban (BAY59-7939) Suspension, BID, Age: 6 - <12 Years | Comparator, Age: 6 - < 12 Years | Total |
|---|---|---|---|---|---|---|
| Female | 8 | 7 | 5 | 6 | 3 | 29 |
| Male | 3 | 6 | 8 | 13 | 4 | 34 |
Ran from Feb 2013 to primary completion in Sep 2016, 42 months.
Results were first posted in Sep 2017, 1 year after primary completion.
Of 16 phase 2 interventional studies under Venous Thrombosis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 42 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban